Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 9/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19510205 | 0.88 | SCN9A (0.78) | SCN9ASCN5ACYP3A4CYP2C8CYP2C9 | |
| SCHEMBL19475858 | 0.88 | SCN9A (1.00) | SCN9ASCN5ACYP3A4CYP2C8CYP2C9 | |
| SCHEMBL19475911 | 0.85 | SCN9A (0.74) | SCN9ASCN5ACYP3A4CYP2C8CYP2C9 | |
| SCHEMBL19475792 | 0.85 | SCN9A (1.00) | SCN9ASCN5A | |
| SCHEMBL19475874 | 0.85 | SCN9A (1.00) | SCN9ASCN5ACYP3A4CYP2C8CYP2C9 | |
| SCHEMBL19475794 | 0.84 | SCN9A (0.73) | SCN9ASCN5ACYP3A4CYP2C8CYP2C9 | |
| SCHEMBL19510011 | 0.83 | SCN9A (0.74) | SCN9ASCN5ACYP3A4CYP2C8CYP2C9 | |
| SCHEMBL19475913 | 0.78 | SCN9A (1.00) | SCN9ASCN5ACYP3A4CYP2C8CYP2C9 | |
| SCHEMBL20914775 | 0.74 | SCN9A (0.77) | SCN9ASCN5ACYP3A4CYP2C8CYP2C9 | |
| SCHEMBL19510533 | 0.74 | SCN9A (1.00) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550080-B2 | Acyl sulfonamide NaV1.7 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-04 | — | — | US | disclosed |
| US-10550080-B2 | Acyl sulfonamide NaV1.7 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190119209-A1 | ACYL SULFONAMIDE NaV1.7 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190119209-A1 | ACYL SULFONAMIDE NaV1.7 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-25 | — | — | US | disclosed |
| WO-2017184658-A1 | ACYL SULFONAMIDE NaV1.7 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550080-B2 | Acyl sulfonamide NaV1.7 inhibitors | SCN7A, SCN1A, SCN8A | SCN9A 10/4885SCN5A 7/4885CYP3A4 2035/4885 |
| US-20190119209-A1 | ACYL SULFONAMIDE NaV1.7 INHIBITORS | SCN7A, SCN1A, SCN8A | SCN9A 10/4885SCN5A 7/4885CYP3A4 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.